CANCER ASSOCIATED GENES AND THEIR PRODUCTS

Abstract: The application discloses cancer-associated genes and their products, especially those identifiable by SEREX. The genes and products are used to identify, track and treat cancer. Preferably the cancer is prostate cancer.

Description: CANCER ASSOCIATED GENES AND THEIR PRODUCTS. The invention relates to isolated nucleic acid sequences which are expressed in cancers, especially prostate cancers, to their protein products and to the use of the nucleic acid and protein products for the identification and treatment of prostate cancers. The prostate gland is an accessory sex gland in males which is wrapped around the urethra as this tube leaves the bladder. The gland secretes an alkaline fluid during ejaculation. Cancer of the prostate gland is very serious and represents the second leading cause of death from cancer in men. Two specific proteins are known to be made in very high concentrations in prostate cancer cells. These are prostatic acid phosphatase (PAP) and prostate specific antigen (PSA). These proteins have been characterised and have been used to follow response to therapy. However, it has been difficult to correlate the presence of these two proteins to the presence of cancer. Accordingly, there is a need to identify new genes and proteins which are associated with the presence of prostate cancer. The inventors have used a technique known as SEREX (Serological Identification of Antigens by Recombinant Expression Cloning) to identity genes which are over-expressed in prostate cancer tissue. This technique was published by Sahin et al (PNAS (USA), 1995, Vol. 92, pages 11810-11813). SEREX uses total RNA isolated from tumour biopsies from which poly(A) + RNA is then isolated. cDNA is then produced using an oligo (dT) primer. The cDNA fragments produced are then cloned into a suitable expression vector, such as a bacteriophage and cloned into a suitable host, such as E.coli. The clones produced are screened with high-titer IgG antibodies in autologous patient serum, to identify antigens associated with the tumour. The inventors have used this technique to identify a number of genes and gene products associated with prostate cancer. Furthermore, preliminary results have found that some antigens identified by this technique have been also identified by the inventors as being associated with other cancers, such as stomach cancer and oesophagial cancer. A first aspect of the invention provides an isolated mammalian nucleic acid molecule selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID.3, SEQ.ID.4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l 1, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.l 8, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66. Preferably the isolated nucleic acid molecule encodes a mammalian antigen which is expressed in higher than normal concentrations in cancer cells, compared with normal non-cancerous cells. Preferably the cancer is prostate cancer. The term "higher than normal concentrations" preferably means that the protein is expressed at a concentration at least 5 times greater in tumour cells than normal cells. The invention also includes, within its scope, nucleic acid molecules complementary to such isolated mammalian nucleic acid molecules. The nucleic acid molecules of the invention may be DNA, cDNA or RNA. In RNA molecules "T" (Thymine) residues may be replaced by "U" (Uridine) residues. Preferably, the isolated mammalian nucleic acid molecule is an isolated human nucleic acid molecule. The invention further provides nucleic acid molecules comprising at least 15 nucleotides capable of specifically hybridising to a sequence included within the sequence of a nucleic acid molecule according to the first aspect of the invention. The hybridising nucleic acid molecule may either be DNA or RNA. Preferably the molecule is at least 90% homologous to the nucleic acid molecule according to the first aspect of the invention. This may be determined by techniques known in the art. The term "specifically hybridising" is intended to mean that the nucleic acid molecule can hybridise to nucleic acid molecules according to the invention under conditions of high stringency. Typical conditions for high stringency include 0.1 x SET, 0.1% SDS at 68°C for 20 minutes. The invention also encompasses variant DNAs and cDNAs which differ from the sequences identified above, but encode the same amino acid sequences as the isolated mammalian nucleic acid molecules, by virtue of redundancy in the genetic code. * Chain-terminating, or "nonsense" codons. ** Also used to specify the initiator formyl-Met-tRNAMet. The Val triplet GUG is therefore "ambiguous" in that it codes both valine and methionine. The genetic code showing mRNA triplets and the amino acids which they code for. The invention also includes within its scope vectors comprising a nucleic acid according to the invention. Such vectors include bacteriophages, phagemids, cosmids and plasmids. Preferably the vectors comprise suitable regulatory sequences, such as promoters and termination sequences which enable the nucleic acid to be expressed upon insertion into a suitable host. Accordingly, the invention also includes hosts comprising such a vector. Preferably the host is E.coli. A second aspect of the invention provides an isolated protein or peptide obtainable from a nucleic acid sequence according to the invention. As indicated above, the genetic code for translating a nucleic acid sequence into an amino acid sequence is well known. The invention further provides polypeptide analogues, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity of location of one or more amino acid residues (deletion analogues containing less than all of the residues specified for the protein, substitution analogues wherein one or more residues specified are replaced by other residues in addition analogues wherein one or more amino acid residues are added to a terminal or medial portion of the polypeptides) and which share some or all properties of the naturally-occurring forms. Preferably such polypeptides comprise between 1 and 20, preferably 1 and 10 amino acid deletions or substitutions. Preferably the protein or peptide is at least 95%, 96%, 97%, 98% or 99% identical to the sequences of the invention. This can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequenςe according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed. The nucleic acids and proteins/peptides of the invention are preferably identifiable using the SEREX method. However, alternative methods, known in the art, may be used to identify nucleic acids and protein/peptides of the invention. These include differential display PCR (DD-PCR), representational difference analysis (RDA) and suppression subtracted hybridisation (SSH). All of the nucleic acid molecules according to the invention and the peptides which they encode are detectable by SEREX (discussed below). The technique uses serum antibodies from prostate cancer patients to identify the molecules. It is therefore the case that the gene products identified by SEREX are able to evoke an immune response in a patient and may be considered as antigens suitable for potentiating further immune reactivity if used as a vaccine. The third aspect of the invention provides the use of nucleic acids or protein/peptides according to the invention, to detect or monitor prostate cancer. The use of a nucleic acid molecule hybridisable under high stringency conditions, a nucleic acid according to the first aspect of the invention to detect or monitor prostate cancer is also encompassed. Such molecules may be used as probes, e.g. using PCR. The expression of genes, and detection of their protein products and/or peptides may be used to monitor disease progression during therapy or as a prognostic indicator of the initial disease status of the patient. There are a number of techniques which may be used to detect the presence of a gene, including the use of Northern blot and reverse transcription polymerase chain reaction (RT-PCR) which may be used on tissue or whole blood samples to detect the presence of cancer associated genes. For protein and/or peptide sequences in-situ staining techniques or enzyme linked ELISA assays or radio-immune assays may be used. RT-PCR based techniques would result in the amplification of messenger RNA of the gene of interest (Sambrook, Fritsch and Maniatis, Molecular Cloning, A Laboratory λ4anual, 2 nd Edition). ELISA based assays necessitate the use of antibodies raised against the protein or peptide sequence and may be used for the detection of antigen in tissue or serum samples (Mclntyre C.A., Rees R.C. et. al, Europ. J. Cancer 28, 58-631 (1990)). In-situ detection of antigen in tissue sections also rely on the use of antibodies, for example, immuno peroxidase staining or alkaline phosphatase staining (Gaepel, J.R., Rees, R.C. et.al, Brit. J. Cancer 64, 880-883 (1991)) to demonstrate expression. Similarly radio-immune assays may be developed whereby antibody conjugated to a radioactive isotope such as I' 25 is used to detect antigen in the blood (Turkes, A., et.al., Prostate-specific antigen - problems in analysis. Europ. J. Cancer. 27, 650-652 (1991)). Blood or tissue samples may be assayed for eleviated concentrations of the nucleic acid molecules, proteins or peptides. Kits for detecting or monitoring cancer, such as prostate cancer, using polypeptides, nucleic acids or antibodies according to the invention are also provided. Such kits may additionally contain instructions and reagents to carry out the detection or monitoring. The fourth aspect of the invention provides for the use of nucleic acid molecules according to the first aspect of the invention or protein/peptide molecules according to the second aspect of the invention in the prophylaxis or treatment of cancer, or pharmaceutically effective fragments thereof. By pharmaceutically effective fragment, we mean a fragment of the molecule which still retains the ability to be a prophylactant or to treat cancer. The cancer may be prostate cancer. The molecules are preferably administered in a pharmaceutically amount. Preferably the dose is between 1 μg/kg. to 10 mg/kg. The nucleic acid molecules may be used to form DNA-based vaccines. From the published literature it is apparent that the development of protein, peptide and DNA based vaccines can promote anti-tumour immune responses. In pre-clinical studies, such vaccines effectively induce a delayed type hypersensitivity response (DTH), cytotoxic T-lymphocyte activity (CTL) effective in causing the destruction (death by lysis or apoptosis) of the cancer cell and the induction of protective or therapeutic immunity. In clinical trials peptide-based vaccines have been shown to promote these immune responses in patients and in some instances cause the regression of secondary malignant disease. Antigens expressed in prostate cancer (or other types of cancers) but not in normal tissue (or only weakly expressed in normal tissue compared to cancer tissue) will allow us to assess their efficacy in the treatment of cancer by immunotherapy. Protein or peptide derived from the tumour antigen may be administered with or without immuno logical adjuvant to promote T-cell responses and induce prophylactic and therapeutic immunity. DNA-based vaccines preferably consist of part or all of the genetic sequence of the tumour antigen inserted into an appropriate expression vector which when injected (for example via the intramuscular, subcutaneous or intradermal route) cause the production of protein and subsequently activate the immune system. An alternative approach to therapy is to use antigen presenting cells (for example, dendritic cells, DCs) either mixed with or pulsed with protein or peptides from the tumour antigen, or transfect DCs with the expression plasmid (preferably inserted into a viral vector which would infect cells and deliver the gene into the cell) allowing the expression of protein and the presentation of appropriate peptide sequences to T-lymphocytes. Accordingly, the invention provides a nucleic acid molecule according to the invention in combination with a pharmaceutically-acceptable carrier. A further aspect of the invention provides a method of prophylaxis or treatment of prostate cancer comprising the administration to a patient of a nucleic acid molecule according to the invention. The protein/peptide molecules according to the invention may be used to produce vaccines to vaccinate males against prostate cancer. Accordingly, the invention provides a protein or peptide according to the invention in combination with a pharmaceutically acceptable carrier. The invention further provides use of a protein or peptide according to the invention in a prophylaxis or treatment of a cancer such as prostate cancer. Methods of prophylaxis or treating prostate cancer, by administering a protein or peptide according to the invention to a patient, are also provided. Vaccines comprising nucleic acid and/or proteins and peptides according to the invention are also provided. The proteins and peptides of the invention may be used to raise antibodies. In order to produce antibodies to tumour-associated antigens procedures may be used to produce polyclonal antiserum (by injecting protein or peptide material into a suitable host) or monoclonal antibodies (raised using hybridoma technology). In addition PHAGE display antibodies may be produced, this offers an alternative procedure to conventional hybridoma methodology. Having raised antibodies which may be of value in detecting tumour antigen in tissues or cells isolated from tissue or blood, their usefulness as therapeutic reagents could be assessed. Antibodies identified for their specific reactivity with tumour antigen may be conjugated either to drugs or to radioisotopes. Upon injection it is anticipated that these antibodies localise at the site of tumour and promote the death of tumour cells through the release of drugs or the conversion of pro-drug to an active metabolite. Alternatively a lethal effect may be delivered by the use of antibodies conjugated to radioisotopes. In the detection of secondary/residual disease, antibody tagged with radioisotope could be used, allowing tumour to be localised and monitored during the course of therapy. The term "antibody" includes intact molecules as well as fragments such as Fa, F(ab') 2 and Fv. The invention accordingly provides a method of treating prostate cancer by the use of one or more antibodies raised against a protein or peptide of the invention. The cancer-associated proteins identified may form targets for therapy. The invention also provides nucleic acid probes capable of binding sequences of the invention under high stringency conditions. These may have sequences complementary to the sequences of the invention and may be used to detect mutations identified by the inventors. Such probes may be labelled by techniques known in the art, e.g. with radioactive or fluorescent labels. The invention will now be described by reference to the following figure and examples: Figure 1 shows RT-PCR of different tumour samples showing over-expression of MTA-1 (SEQ.ID.57). Technique used to identify genes encoding tumour antigens (SEREX technique) The technique for the expression of cDNA libraries from human prostate cancer tissue is described, and was performed according to published methodology (Sahin et.al. Proc Natl. Acad. Sci. 92, 11810-11813, 1995). SEREX has been used to analyze gene expression in tumour tissues from human melanoma, renal cell cancer, astrocytoma, oesophageal squamous cell carcinoma, colon cancer, lung cancer and Hodgkin's disease. Sequence analysis revealed that several different antigens, including HOM-MEL-40, HOM-HD-397, HOM-RCC-1.14, NY- ESO-1, NY-LU-12, NY-CO- 13 and MAGE genes, were expressed in these malignancies, demonstrating that several human tumour types express multiple antigens capable of eliciting an immune response in the autologous host. This represents an alternative and more efficient approach to identify tumour markers, and offers distinct advantages over previously used techniques: 1) the use of fresh tumour specimens to produce the cDNA libraries obviates the need to culture tumour cells in vitro and therefore circumvents artefacts, such as loss or neo-antigen expression and genetic and phenotypic diversity generated by extended culture; 2) the analysis is restricted to antigen-encoding genes expressed by the tumour in vivo; 3) using cDNA expression cloning, the serological analysis (in contrast to autologous typing) is not restricted to cell surface antigens, but covers a more extensive repertoire of cancer-associated proteins (cytosolic, nuclear, membrane, etc.); 4) in contrast to techniques using monoclonal antibodies, SEREX uses poly-specific sera to scrutinise single antigens that are highly enriched in lytic bacterial plaques allowing the efficient molecular identification of antigens following sequencing of the cDNA. Subsequently the tissue-expression spectrum of the antigen can be determined by the analysis of the mRNA expression patterns using northern blotting and reverse transcription-PCR (RT-PCR), on fresh normal and malignant (autologous and allogeneic) tissues. Likewise, the prevalence of antibody in cohorts of cancer patients and normal controls can be determined. Construction of cDNA expression libraries, screening and sequencing The detailed methodology for SEREX expression cloning established by the inventors is as follows: Total RNA is isolated from fresh prostate cancer tissues using the guanidinium thiocyanate-phenol-chloroform extraction method; RNA integrity is determined by electrophoresis in formalin/MOPS gels. Poly(A)+ RNA is prepared by applying the prepared RNA sample to a column of oligo (dT) cellulose and cDNA expression libraries is constructed from 5-8 μg of poly(A)+ RNA; first-strand synthesis is performed using an oligo(dT) primer with an internal XJw I site and 5-methyl-CTP. cDNA is ligated to EcoRI adaptors and digested with Xho I and cDNA fragments are cloned directionally into the bacterophage expression vector, packaged into phage particles, and used to transfect Escherichia coli. Immuno-screening for the detection of clones reactive with antibodies present in diluted autologous serum is then performed. Transfection for primary screening and plaque transfer onto nitrocellulose membranes is followed by pre-incubation of the membranes with an alkaline phosphatase-conjugated antibody specific for human IgG. Reactive clones representing expressed IgG heavy chains visualized by staining are eliminated from the study. These pre-stained membranes are then incubated with the autologous patient serum, and binding to recombinant proteins expressed in lytic plaques detected by incubation with an alkaline phosphatse-conjugated goat anti-human IgG, and differentiated from the IgG-heavy chain transcripts. The reactive clones are sub-cloned, purified, and in vitro excised to pBK-CMV plasmid forms. Plasmid DNA is prepared using the Wizard (Trade Mark) Miniprep DNA purification system (Promega Corp., Southampton, UK). The inserted DNA is evaluated by restriction mapping, and clones representing different cDNA inserts sequenced using the automated sequencer. Expression of Antigens in Different Cancers The expression of metastasis associated 1 (MTA1) (SEQ.ID.57) in cancer samples was compared with that in corresponding normal tissues by semi-quantitative reverse- transcription polymerase chain reaction (RT-PCR). RT-PCR was carried out using processes well known in the literature. A relative over-expression of MTA1 mRNA (normal/tumour ratio>2) was observed in esophageal cancer (3/7) and head and neck tumour (1/7) (Table 1). See Figure 1, tracks 6 and 8. Testis did not show any over-expression. GAPDH (Glyceraldehyde-3-phosphate Dehydrogenase) expression was also tested as a control. No difference in expression was normal tissue and observed between tumours. Table 1 Tumour type Positive rate Esophageal cancer 3/7 Head and neck tumour 1/7 Table 2 shows the results of further studies of a variety of sequences in different tumours. " - " indicates not studied. This table shows that the proteins are immunogenic in a higher portion of patients with cancer than controls since the patients have antibodies against the cloned protein product. Table 2 Serological responses in cancer patients and controls to tbe protein products of ςeπes cloned from the ΛNA libra rv nsine SEREX. Immunoscreening with sera from • :Q ID # Gene size bp Identity Controls BPH Prostate Ca Head & Neck Ca Co Ca Ga Ca 8 Pr III-41 3500 Unknown 0/7 - 4/10 2/4 - 137,144 10 Priπ-90 3000 Unknown 0/10 0/2 m 2/4 - 102,108 12 Pr III-104 1500 Unknown 0/& 0/2 2/7 2/4 - 16 Pt DI-133 1550 Unknown 0/5 0/2 4/7 - - 18 Pr III-147 1100 Unknown 1/10 0/2 8/12 2/4 0/2 50 Pr DI-157 400 Hu Ribosoma! 0/4 - 5/10 1/4 - Protein S10 57 Pr III-176 2600 MTA1 0/13 0/3 2/13 - 0/2 0/2 60 Pr IU-197 1200 ALG2 1/17 0/3 4/13 3/4 0/2 0/2 29 PrIH-213 2500 Unknown 0/6 0/2 4/12 2/4 0/2 Serum samples from: Controls BPH- Benign Prostatic Hypcrplasia Prostate Cancer Head and Neck Cancers Co Ca- Colon Cancer Ga Ca- Gastric Cancer Table 3 shows some of the mutations identified by the inventors. Table 3 Mutations detected in the sequence of genes cloned by SEREX. SEQ ID 1 PR2-7A Human mRNA for KIAA0160 gene GGCGGCTCGGGGCCCAGCGCGGGGTCCGGGGGAGGCGGCTTCGGGGGTTCGGCGGCGGT GGCGGCGGCGACGGCTTCGGGCGGCAAATCCGGCGGCGGGAGCTGTGGAGGGGGTGGCA GTTACTCGGCCTCCTCCTCCTCCTCCGCGGCGGCAGCGGCGGGGGCTGCGGTGTTACCGGT GAAGAAGCCGAAAATGGAGCACGTCCAGGCTGACCACGAGCTTTTCCTCCAGGCCTTTGA GAAGCCAACACAGATCTATAGATTTCTTCGAACTCGGAATCTCATAGCACCAATATTTTTG CACAGAACTCTTACTTACATGTCTCATCGAAACTCCAGAACAAACATCAAAAGGAAAACA TTTAAAGTTGATGATATGTTATCAAAAGTAGAGAAAATGAAAGGAGAGCAAGAA SEQ ID 2 PR2-1 A Human protein immuno-reactive with anti-PTH polyclonal antibodies mRNA ACAGGTGAAAAACCAAATACTTTCTAGGGATGACCTTGATGACATAATTCAGTCATCTCA AACAGTCTCAGAGGACGGTGACTCGCTTTGCTGTAATTGTAAGAATGTCATATTACTCATT GATCAACATGAAATGAAGTGTAAAGATTGTGTTCACCTATTGAAAATTAAAAAGCATTTT GTTTATGTAAAAGATTAACAGAACTTAAAGATAATCACTGTGAGCAACTTAGAGTAAAAA TTCGAAAACTGAAAAATAAGGCTAGTGTACTACAAAAGAGACTATCTGAAAAAGAAGAA ATAAAATCGCAGTTAAAGCATGAAACACTTGAATTGGAAAAAGAACTCTGTAGTTTGAGA TTTGGCCTACAGCAAGAAAAAAAGAAAAGAAGAAATGTTGA ' SEQ ID 3 PR2-21 2 Human JK-recombination signal binding protein (RBPJK) gene GAGAGTTTGTGGAAGATGGCGCCTGTTGTGACAGGGAAATTTGGTGAGCGGCCTCCACCT AAACGACTTACTAGGGAAGCTATGCGAAATTATTTAAAAGAGCGAGGGGATCAAACAGT ACTTATTCTTCATGCAAAAGTTGCACAGAAGTCATATGGAAATGAAAAAAGGTTTTTTTGC CCACCTCCTTGTGTATATCTTATGGGCAGTGGATGGAAGAAAAAAAAAGAACAAATGGAA CGCGATGGTTGTTCTGAACAAGAGTCTCAACCGTGTGCATTTATTGGGATAGGAAATAGT GACCAAGAAATGCAGCAGCTAAACTTGGAAGGAAAGACTATTGCACAGGCAAAACATTG TATATATCTGACTA SEQ ID 4 PR2-5A Human mRNA for E6-AP isoform-I GATTCGGAGAATGATGGAGACATTTCAGCAACTTATTACTTATAAAGTCATAAGCAATGA ATTTAACAGTCGAAATCTAGTGAATGATGATGATGCCATTGTTGCTGCTTCGAAGTGCTTG AAAATGGTTTACTATGCAAATGTAGTGGGAGGGGAAGTGGACACAAATCACAATGAAGA AGATGATGAAGAGCCCATCCCTGAGTCCAGCGAGCTGACACTTCAGGGAACTTTTGGGAG AAGAAAGAAGAAACAAGAAAGGTTCCTCGAGTGGACCCCCTGGAAACTGAACTTGGTGTT AAAACCCTGGATTGTCGAAAACCACTTATCCCTTTTGAAGAGTTTATTAATGAACCACTGA ATGAGGTTCTAGAAATGGATAAGATTTACTTTT SEQ ID 5 PR2-20 3 Human mRNA for TPRD GGAATATGTCTTACCCCTGACTGTGAAGGTGTCATTTCTAAGATTATCATCTTCAGCAGTG GTGGTGAAGTTAAATGTGAATTTGAACACAAGGTCATAAAAGAAAAGGTTCCTCCAAGAC CTATTCTGAAACAGAAATGTTCTAGCCTAGAGAAACTAAGACTGAAAGAAGACAAAAAAT TGAAGAGAAAGATCCAAAAAAAAGAAGCAAAAAAGTTAGCACAAGAAAGAATGGAGGA GGACTTAAGAGAAAGTAATCCACCCAAAAATGAAGACAGAAAGAAACTGTAGACAATGT TCAAGCGTTGTCAGTTCCTTGATGACAGAATTCTACAGTGTATAAAGCAGTATGCTTGACA GGATTAAATCCGGCATACAGAATACAGCCATGCTTCTAAAGAATTGTTT SEQ ID 6 PR2-1B Unknown GGGAAGCAGAAGGATTTGGAGTTTCTTTTTAAAGTGATTCCTTCCTTTCCCCTTTCATTTTT CCACTGTGGGTGTTATTATCCTGACAATTTGTCATACATTTCCTGTCTTTAAAAAATAACTG TATACTAAGCAAAACTCAGGTCTTAAAAATAAATATGAATTTAGATTCCATACATCGATTA ATTGAGGAAACACAGATCTTCCAGATGCAACAATCATCAATTAAGTCACGCGGCGACATG GTGGCCCCTGCCTCACCCCCCAGGGATACCTGTAATACCTGCTTCCCACTTCATGGGCTAC AATCTCATGCTGTCACAATTTCTGTGCTCACTCATATAACACCACAAATGGGATATTTGTG AAGAACTTCGCTGCGGAGCT SEQ ID 7 PR2-2 Unknown AGGGACAGCTCTTGCATCGAGACCCCTTCACTGTCATCTGTGGCCGAAAGAAGTGCCTTCG CCATGTCTTTCTCTTCGAGCATCTCCTCCTGTTCAGCAAGCTCAAGGGCCCTGAAGGGGGG TCAGAGATGTTTGTTTACAAGCAGGCCTTTAAGACTGCTGATATGGGGCTGACAGAAAAC ATCGGGGACAGCGGACTCTGCTTTGAGTTGTGGTTTCGGCGGCGGCGTGCACGAGAGGCA TACACTCTGCAGGCAACCTCACCAGAGATCAAACTCAAGTGGACAAGTTCTATTGCCCAG CTGCTGTGGAGACAGGCAAGCCCACAACAAGGAGCTCCGAGTGCAGCAGATGGTGTCATG GCATTGGGAATAAACCCTTCTGGACATAAAGCCCTTGGGGAGCGA SEQ ID 8 Pr3-4I Unknown GCGGCGGCGGCCCCTCGCAGCAGCTGGCCGGCGGGCCCCCCCAGCA GTTCGCGCTCTCCAACTCCGCGGCCATCCGGGCCGAGATCCAGCGCT TCGAGTCCGTGCATCCCAATATCTACGCCATCTACGACCTGATCGAGC GCATCGAGGATTTGGCGCTGCAGAACCAGATCCGGGAGCACGTCATC TCCATCGAGGACTCGTTTGTGAACAGCCAGGAGTGGACGCTGAGCCG CTCCGTACCGGAGCTTAAAGTGGGCATAGTGGGGAACCTGTCTAGCG GGAAGTCAAGCCCTGGTGCACCGCTATCTGACGGGGACCTATGTCCA GGAGGAGTCCCCTGAAGGGGGGCGGTTTAAGAAGGAGATTGTGGTG GATGGCAGAGTTCCTGCTGTGATC SEQ ID 9 Pr3-42 Unknown GGCTGGCAGTAGAGGTGACCGAGGCGGTGGCGGCGGAGGCGGCACC GATTGCTGTGTCGGCCCCAGTGCGGCCGAAGTCGCGGTAGAGCGTAG CCCCACGCCCCTCCCCCGTCCGCGCCCTCCCTCTTTCCCTGGGGATG GAGAAGGCGACGGTTCCTGGTGGCGGCGGCGACGGCTTGCAGAAGG AGAAGGGAGCCCCCCGGCGGTGGCGGCTTGTGGCGGGCCCCCCCGC GGCGGCGGAGGTCGGCGGCGGCGTTGGCGGCAGCAGCAGAGCTCGC TCGGCCTCGTCTCCTCGTGGGATGGTGCGAGTCTGCGACCTGCTCCT GAAGAAGAAGCCGCCGCAGCAGCAGCACCACAAGGCCAAGCGTAAC CGGACTTGCCACCCCCCAGCAGCAGCGAAAC SEQ ID 10 Pr3-90 Unknown GCGGCGGCGGCCCCTCGCAGCAGCTGGCCGGCGGGCCCCCCCAGCA GTTCGCGCTCTCCAACTCCGCGGCCATCCGGGCCGAGATCCAGCGCT TCGAGTCCGTGCATCCCAATATCTACGCCATCTACGACCTGATCGAGC GCATCGAGGATTTGGCGCTGCAGAACCAGATCCGGGAGCACGTCATC TCCATCGAGGACTCGTTTGTGAACAGCCAGGAGTGGACGCTTGAGCC GCTCCGTACCGGAGCTTAAAGTGGGCATAGTGGGGAACCTGTCTAGC GGGAAGTCAGCCCTGGTGCACCGCTATCTGACGGGGACCTATGTCCA GGAGGAGTCCCTGAAGGGGGGCGGTTAAGAAGGAGATTGTGGTGGA TGGCAGAGTTCCTGCTGC SEQ ID 11 Pr3-93 Unknown ATTATGAAGTAACTGAACTTTTGGTCAAGCATGGTGCCTGTGTAAATG CAATGGACTTGTGGCAATTCACTCCTCTTCATGAGGCAGCTTCTAAGA ACAGGGTTGAAGTATGTTCTCTTCTCTTAAGTTATGGTGCAGACCCAA CACTGCTCAATTGTCACAATAAAAGTGCTATAGACTTGGCTCCCACAC CACAGTTAAAAGAAAGATTAGCATATGAATTTAAAGGCCACTCGTTGC TGCAAGCTGCACGAGAAGCTGATGTTACTCGAATCAAAAAACATCTCT CTCTGGAAATGGTGAATTTCAAGCATCCTCAAACACATGAAACAGCAT TGCATTGTGCTGCTGCATCTCCATATCCCAAAAGAAAGCAAATATGTG AACTGTTGCTAGAAAAGC SEQ ID 12 Pr3- 104 Unknown CCTCAGCATACCCACCGAGCAGCTGCCAGCCTGGGCTGAGGGTGGGC ATGAGGCAGGAGTCAGCACTTGGACCTAGGGATGTGAGGTTTTCTGT GCCCCAAGTTTGTGGGAAGGTGGGCACTACTGCTGGGCCCACAGACA CAGCCAGCTGGCAAAAGGGAGGTCTAGCCCAGCAGAGAGATGAGGA CATTTTGCTTCTCCTTCATGCCCACAGCATGAGCTGAGCTTCTGCTTT GCTGGAAATGAAATAAACTTGGTATGAATTGTGCCAAGGCCTCCCCA GTTGTCATCCTGCCTCTTGTTGCCCTCCCTTGTCCTTGCCCCCCACCC CACACCCATGCCCCTGTTTCCTTACAGATTTTGATATTGTCTAATGTG TAATAGAACCAGCCGAGTCCCA SEQ ID 13 Pr3-113 Unknown CTTACCTCATTTCTGAATGTGCATTTCCAGCCTTCTTGCTCTCAGAGC TATTGTTCAAGCAGAAAACAAGCTGCTTTTATTACA SEQ ID 14 Pr3- 122 Unknown GAGAGAACTAGTCTCGAGTTTTTTTTTTATTCTTCTATATTCTATGAAT ATGGTGCTGTCCTGTCATTTAATTATTATAATATATGTGAACTGCTGG AGGTAAA SEQ ID 15 Pr3-124 Unknown TCGATCCTTAGTGACTTAACAATCAGGCCTTAATTGAAACACACACAC ACATTGTTATTGACAGTGTAGAAATACTGACTCATAGAAAAATTCACC CATATTTAGTTAGCAGACTAACAGGAACAGCAGCAGCAGCAGCAGCT GGTCATGCTTCTGTGTGTTGCTAGCAACAAGAAACCATGACAGCAAG GCCCCAAACAGGAACCTCCTGCATTTTCTCATCTGTGATGAGGCACAC TTGATGCTGGGGATTAATGAGCCTGAAGATATAAAGCAGTGTTTACC ACTGGAAAATGTCTCCTACACTAAAAGCAGAGGTAAGTATCAATGCA AACCGAGTGCAGCTATAAAGCCTTGATTTCTCTGGAAATTATGTACAA ACTAATACAAATAATCTCATTACTTGAAAC SEQ ID 16 Pr3-133 Unknown GCTACGGCTGCTCCGGAGCTGGTGGCGCCGCGATAGGAGAGCCGAT GGCCAAGTGGGGTGAGGGAGACCCACGCTGGATCGTGGAGGAGCGG GCGGACGCCACCAACGTCAACAACTGGCACTGGACGGAGAGAGATGC TTCAAATTGGTCCACGGATAAGCTGAAAACACTGTTCTTGGCAGTGCA GGTTCAAAATGAAGAAGTCAAGTGTGAGGTGACGGAAGTGAGTAAGC TTGATGGAGAGTCATCCATTAACAATCGCAAAGGGAAACTTATCTTCT TTTATGAATGGAGCGTCAAACTAAACTGGACAGGTACTTCTAAGTCAG GAGTACAGTACAAAGGACATGAGGAGATCCCCAATTTGTCTGATGAA AAC SEQ ID 17 Pr3-140 Unknown CATTACCTTACAGTGTAAACAGGAGTCTAATTTGTATCAATACTATGT TTTGGTTGTAATATTCAGTTCACTCACCCAATGTACAACCAATGAAAT AAAAGAAGCATTTAAAAGGAA SEQ ID 18 Pr3- 147 Unknown GGCGTGTGGGTCTCGCAGCGTTGCTCACAGAACAGAGTAGAGGCGGC GGCGGCGGCGGCCGGACCCAGACTGGTAGTGAGGCGTTGGACCCCG AGCCGCTGCAATGCCGCTGGAGCTGGAGCTGTGTCCCGGGCGCTGG GTGGGCGGGCAACACCCGTGCTTCATCATTGNCGAGATCGGCCAGAA CCACCAGGGCGACCTGGACGTAGCCAAGCGCATGATCCGCATGGCCA AGGAGTGTGGGGCTGATTGTGCCAAGTTCCAGAAGAGTGAGCTAGAA TTCAAGTTTAATCGGAAAGCCTTGGACAGGCCATACACCTCGAAGCA TTCCTGGGGGAAGACGTACGGGGAGCACAAACGACATCTGGAGTTCA GCCATGACCAGTCAGGGAGCTGAGAGGTCC SEQ ID 19 Pr3-148 Unknown GACGGACCGAGACCGGAGATGTTTTCAAGCCCGGCTCCGGCGGCTTT ACAGGCGGCTGCAGCGGCGACGAAGACAACGACAGCGACGGCTACG CCGAAGCACTCGAACCGGGGGTGAAGCCTCCTGCGCCGGCCTTGCCT CGGATCCAGGATGAGAAGACTGATAAAAGAAGAAGCTAGCTGAACAG CTGTAAAATGCCCAAATCTGGGTTCACAAAACCAATTCAGAGTGAAAA TTCTGACAGTGACAGCAATATGGTAGAGAAACCATATGGAAGAAAGA GTAAAGACAAGATTGCATCCTACAGCAAAACTCCAAAAATTGAACGA AGTGATGTGAGCAAGGAGATGAAAGAGAAATCATCCATGAAACCGTA AACTTCCTTTC SEQ ID 20 Pr3- 162 Unknown GCAGGAGGGGCCTTGCCAGCTTCCGCCGCCGCGTCGTTTCAGGACCCGGACGGCGGA TTCGCGCTGCCTCCGCCGCCGCGGGGCAGCCGGGGGGCAGGGAGCCCAGCGAGGGGC GCGCGTGGGCGCGGCCATGGGACTGCGCCGGATCCGGTGACAGCAGGGAGCCAAGCG GCCGGGCCCTGAGCGCGTCTTCTCCGGGGGGCCTCGCCCTCCTGCTCGCGGGGCCGG GGCTCCTGCTCCGGTTGCTGGCGCTGTTGCTGGCTGTGGCGGCGGCCAGGATCATGT CGGGTCGCCGCTGCGCCGGCGGGGGAGCGGCTGCGCGAGCGCCGCGGCCGAGGCCGT GGAGCCGGCCGCCGAAGCTGTTCGAGGCGTGCCGAACGGGGACGTGGAACGAGTAAG AGGCTG SEQ ID 21 Pr3- 180 Unknown GCCAACTCAGTCCAGCAGAACAAAATGTAGCTGCCATTCTTGGAGTC TCTGAAAGCTTTATTGGGAAGAAAGCATCAGGCCAAGCCATCGGAAA GAAGGTGGACAAGAACGTTGTCAACAGGCTATATCTGTCTTTTGTTCT TTATACCTTGCTCAAAGAGACCAACATTTGGACTGTATCTGAAAAATT TAATATGCCTCGAGGATATATACAAAATCTTCTCACTGGAACTGCCTC ATTCTCATCTTGTGTGTTACATTTCTGTGAGGAGCTTGAGGGAGTTTT GGGTTTACAGAGCCCTTTTGGTAGAACTTACCAAGAAGCTGACTACT GTGTAAAGGGCAGAATTAATCCCTCTATGGGAAGTTCTNGGAGTTTTA GAGGGTCGAGCAAAACAGTTTTTCAGNGCCNGGTACCAAAAGTCTAA TGCCTTAGCTAAGCAAACCCTGAANGNTTCTANGGNCAATTGGTCNTT TTTTAAGACCCCAAGCCAGCAAATTGTTTATNCAAAAATCTNTTCNTN AAAACCAAACCTCAAAANGGNNAAAAGTCCNAAATGCTTTTNTTCCCG GGGGNGGGGGTTNTTCCCGGCAAACNGAANTTTTTGNGGGAANTTTT TTTTAATTTTTTTNG SEQ ID 22 Pr3-187 unknown GGGAGGCGGCGGCAGCGTTAAGTGAGAAAGGAAAAAAGACAACGAGGAAAAAGGAGG TGTCCGGGTAGGGCAACGCGGCGACACCCGAGGCCTGGTGGTGGCGGCGGATCGAGA TATTCAAGGCTGAAGCAGCTACGGAACGGCAGCGGCGGCGGTCGGACAAACTGACTG ACCGAGCCGGGTGGTGGCGGGAGCAGCGGGAGCAGCCGGAACGATGCCGGCCGTGAG CCTCCCGCCCAAGGAGAATGCGCTCTTCAAGCGGATCTTGAGGTGTTATGAACATAA ACAGTATAGAAATGGATTGAAATTCTGTAAACAAATACTTTCTAATCCCAAATTTGC AGAGCATGGAGAAACCTTGGCTATGAAAGGATTAACATTGAACTGTTTGGGGAAAAA GGAAGAACTTATGAATTGGTTCCTAGAGGTTTGAGAAATGACTTGAAGAGTCATGTG TGTTGGCCACGTTTATGGCCTTTTTCAAGGTCANACAAGAAGTNTGATGAANNCCTT AANTGTTACAGAAATGCCTAAATGGGATAAGACATCTTAAATTTTAAGGGNCTTTCT TCTACAANTCAATCCAAACTNGNGGNTTCCNGGAACCAGGTTTNANTTCTTCANTTN CNCCTCCCAAAGCATTATGNT SEQ ID 23 Pr3- 194 Unknown CGGTGGCGGCGGAGGCGGCACCGATTGCTGTGTCGGCCCCAGTGCGGCCGAAGTCGC GGTAGAGCGTAGCCCCACGCCCCTCCCCCGTCCGCGCCCTCCCTCTTTCCCTGGGGA TGGAGAAGGCGACGGTTCCGGTGGCGGCGGCGACGGCTGCAGAAGGAGAAGGGAGCC CCCCGGCGGTGGCGGCTGTGGCGGGCCCCCCCGCGGCGGCGGAGGTCGGCGGCGGCG TTGGCGGCAGCAGCAGAGCTCGCTCGGCCTCGTCTCCTCGTGGGATGGTGCGAGTCT GCGACCTGCTCCTGAAGAAGAAGCCGCCGCAGCAGCAGCACCACAAGGCCAAGCGTA ACCGGACTTGCCGACCCCCCAGCAGCAGCGAAAGCAGCAGCGACAGCGACAACAGCG GCGGCGGTGGAGGCGGCGGTGGAGCGGAAGTGGCGGCGGCGGCACCAGCANTAACAA CAGCGAGGAAANAAAGGACACACACCAGGAANAGAGGTTNTGAGGGGAGTTTTATTT GGNTCAGATTATTGGAAANTCAANCTTGNAAACTTCCAGGTNNTCTATAANGTCNNT TGTNGNGCATACNTANGAANTANNCCAAAANNAGNTTTNATGGGAGTTTTACNAAAC NCAGTTTGGATC SEQ ID 24 Pr3-199 Unknown CTNNGTTTTTTTTTTTTTTTTTTTCCAGACTCTTCTGTTCTTTTATATCTCAGAAAG GATTGGGTTTTCAGGTTGCAAAATCTTTTCCAGCTCTGCATAGGTAGGTAGCATCTC ACTGAGGAATGGAGTATTTACCACCTATTGTTCTGTNCCAGTCTAGTAGAGCTTTAG CAAAANCTACAGGCAACAAATTCTATTTTTAACATCCTGTTACACAAACAAATATGC TGAGTATGCACACAAATAAATGGTGAAAGAGGCNCAAAGAAGTGAAAACAATCGTGC ATGGTAGGAATATTTGAATTGTNTTACATGTCCTTTAATATTGNTTTAACAGTNATA TTTTTACATTTTCAATTGGAATGAAAAGCATGTCTGTGTTCGAATAATTTTTCATCG NNCNCTCATTTTTTTGATTCCCNANCTAATGAGNAGAAANCAGTGATGATTGCAAAA TGTTTCCCNCCCTNAAGGAATNCNCGTNNGAATTCTTGCAGNTCCTGGAGANCTCCN TANTTTANGNCNTATATAGGTANNGATCTATACTCCCTCGGGGGGTCTTAGCCTNNC GCNNCCTNCCTTCCNTCTCACNANCATTGTTNTCTANNGCNNCTCANNTAANTNCTN CAGGCCCNCAANTGNNTATNNANCCNCNNNCNTNTC SEQ ID 25 Pr3-201 Unknown CCCGGAACCTGCAAGGCCTGGTCTGGGACCCACACAACCGTAGGAGA CAGGTCCTGAATACCCGGGCCCAAGAGCCCAAGCTGTGCTGGCCTCA GGGTTTCTCCTGGAGTCACCGAGCCGTGGTCCACTTCGTCGTGCCTG TGAAGAACCAGGCACGCTGGGTACAGCAATTCATCAAAGACATGGAA AACCTGTTCCAGGTCACCGGTGACCCACACTTCAACATCGTCATCACT GACTATAGCAGTGAGGACATGGATGTTGAGATGGCACTGAAGAGGTC CAAGCTGCGGAGCTACCAGTACGTGAAGCTAAGTGGAAACTTTGAAC GCTCAGCTGGACTTCAGGCTGGCATAGACCTCGTGAAGGACCCGCAC AGCATCATCTTCCTcTGTGACCTCCACATCACTTCCCACTTGGAGTCA TNGATGCCATTCGGAACACTTGTGTGGAGGGAAAAGAAGGGCTTTTG CCCCCTGGTGATAAGGTTGNNTTGGGGGCNCCCCCAANGGCTGAGGC TCGGGAGGGAAAAGGGTTGGGNNTTGGATTTACAATTTNCCTGANAN GATGGGGGCNTAACCAAAAGGANTCCAAANCCTGGGNGGGAAAAANG GNACTTTTNNAGGAATTTCAANGCN SEQ ID 26 Pr3-202 Unknown GTGAGATGAATGTTCCCCCTTCAATTCTCCTTATTTGCCAAATATTTT CATTTCCTTTTGTCATTATAGAAAATAAAACCATGCATCACA SEQ ID 27 Pr3-205 Unknown AGGAACCAAAGAAGACATGGTCCCTGTCCTCATGGTTCAGACAGGGAGGCAGACATT AAACAACTAATTATCAGTTATTCAATTA SEQ ID 28 Pr3-208 Unknown GCGACTCGGGGACCTGGAGCTGACGCCTAGACACTTGTATTAGCTTT AATAGAAGAGAAATGGAGGAGCCATAGAATATTAAGGATGAATTCAG GAAGGCCTGAGACCATGGAAAACTTGCCTGCTCTCTACACTATTTTCC AAGGAGAGGTTGCTATGGTGACAGACTATGGGGCCTTTATCAAAATC CCAGGCTGTCGGAAGCAAGGTCTGGTCCATCGAACTCATATGTCATC CTGTCGGGTGGATAAGCCCTCTGAGATAGTAGATGTTGGAGATAAAG TGTGGGTGAAGCTTATTGGCCGAGAGATGAAAAATGATAGAATAAAA GTATCCCTCTCCATGAAGGTTGTCAATCAAGGGGACTGGGAAAGACC TTGATCCCAACAATGTTATCATTGAGCAAGAAGAGANGCGGAGGCGA TCCTTCCAGGATTACACTGGGCAGNAAGATCACCCTTGAGGCTTGTCT TGACCCTACCTCAANAAGNGNGGNTGTAAAGGGCCCTTTGCAAAAAA TGGTTATGCANCNGGGGGAATTAAACTTTTTTTCCNTTGGGAAAGGAA AGGAAAGCCAATCCCCANTTTGNAAACCTNCCTCAGGAATCTTTTAAA NAAAGAGGGAAAAAAAANAACCN SEQ ID 29 Pr3-213 Unknown CTGTCATGGCTGCTCCTGTACGTAGTCACGGTCTTGTGCTCTAAGGAA AACGACAGCACGTGTTCTTTTTCACTAGTAGAAGTGACGTTGGTTTCA TGTTGACAACTTTGAAGCCATTTGGAAGTGTTTCAGTGGAGAACAAAA TGAATAACAAAGCGGGCTCCTTTTTCTGGAACCTTAGACAATTCAGTA CATTAGTTTCAACAAGCAGAACTATGAGGCTATGTTGTTTGGGACTTT GCAAACCAAAAATAGTTCATTCAAACTGGAACATTTTAAATAACTTTC ATAACAGAATGCAATCAACTGATATCATTAGATATCTCTTTCAGGATG CATTCATTTTTAAATCAGATGTTGGCTTTCAAACAAAGGGCATAAGCC TCTACAGCCCTTAGAATTGAAGAC SEQ ID 30 Pr3 -214 Unknown GTATGGCGGCGTCAAAGGTGAAGCAGGACATGCCTCCGCCGGGGGG CTATGGGCCCATCGACTACAAACGGAACTTGCCGCGTCGAGGACTGT CGGGCTACAGCATGCTGGCCATAGGGATTGGAACCCTGATCTACGGG CACTGGAGCATAATGAAGTGGAACCGTGAGCGCAGGCGCCTACAAAT CGAGGACTTCGAGGCTCGCATCGCGCTGTTGCCACTGTTACAGGCAG AAACCGACCGGAGGACCTTGCAGATGCTTCGGGAGAACCTGGAGGAG GAGGCCATCATCATGAAGGACGTGCCCGACTGGAAGGTGGGGGAGT CTGTGTTCCACACAACCCGCTGGGTGCCCCCCTTGATCGGGGAGCTG TACGGCTTGCGCACCACAGAGGAGGCTCTTCATGCCAGCC SEQ ID 31 Pr3-2 Homo sapiens geminin mRNA GCAGGGCTTTACTGCAGAGCGCGCCGGGCACTCCAGCGACCGTGGG GATCAGCGTAGGTGAGCTGTGGCCTTTTGCGAGGTGCTGCAGCCATA GCTACGTGCGTTCGCTACGAGGATTGAGCGTCTCCACCCATCTTCTGT GCTTCACCATCTACATAATGAATCCCAGTATGAAGCAGAACAAGAAG AAATCAAAGAGAATATAAAGAATAGTTCTGTCCCAAGAAGAACTCTGA AGATGATTCAGCCTTCTGCATCTGGATCTCTTGTTGGAAGAGAAAATG AGCTGTCCGCAGGCTTGTCCAAAAGGAAACATCGGAATGACCACTTA ACATCTACAACTTCCAGCCCTGGGGTTATTGTCCCAGAATCTAGTGAA AATAAAATCTTGGAGGAGTACCCAGGA SEQ ID 32 Pr3-8 Homo sapiens scaffold attachment factor A GCGAACTCGGTGAAAGGAATTGGCGCCGTTCGACACCAGGCGGATCC GCTCTGCAGCACGAACCCATCTCCAGCCGCAGCCGCAGCCGCCGCCC GGGCCGAGGAGCAGCCGCAGCAGCCGCACCAGTGGCCGAGTGAGCG GAGCCGAGTTTGAGGCAGCGCCTAGCGGTGAATCGGGGCCCTCACCA TGAGTTCCTCGCCTGTTAATGTAAAAAAGCTGAAGGTGTCGGAGCTG AAAGAGGAGCTCAAGAAGCGACGCCTTTCTGACAAGGGTCTCAAGGC CGAGCTCATGGAGCGACTCCAGGCTGCGCTGGACGACGAGGAGGCC GGGGGCCGCCCCGCCATGGAGCCCGGGAACGGCAGCCTAGACCTGG GCGGGGATTCCGCTGGGA SEQ ID 33 Pr3-11 Homo sapiens ribosomal protein L32 CCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCATGGCCGCCCTC AGACCCCTTGTGAAGCCCAAGATCGTCAAAAAGAGAACCAAGAAGTT CATCCGGCACCAGTCAGACCGATATGTCAAAATTAAGCGTAACTGGC GGAAACCCAGAGGCATTGACAACAGGGTTCGTAGAAGATTCAAGGGC CAGATCTTGATGCCCAACATTGGTTATGGAAGCAACAAAAAAACAAA GCACATGCTGCCCAGTGGCTTCCGGAAGTTCCTGGTCCACAACGTCA AGGAGCTGGAAAGTGCTGCTGATGTGCAACAAATCTTACTGTGCCGA GATCGCTNACAATGTTTCTTCAAGACCGCAAAGCC SEQ ID 34 Pr3-13 Homo sapiens glutamyl-prolyl-tRNA synthetase GTCGGGTACGCGCACACGTTGCATCTTCTTCCTTTCGCGGGGTCCTC CGTAGTTCTGGCACGAGCCAGGCGTACTGACAGGTGGACCAGCGGAC TGGTGGAGATGGCGACGCTCTCTCTGACCGTGAATTCAGGAGACCCT CCGCTAGGAGCTTTGCTGGCAGTAGAACACGTGAAAGACGATGTCAG CATTTCCGTTGAAGAAGGGAAAGAGAATATTCTTCATGTTTCTGAAAA TGTGATATTCACAGATGTGAATTCTATACTTCGCTACTTGGCTAGAGT TGCAACTACAGCTGGGTTATATGGCTCTAATCTGATGGAACATACTGA GATTGATCACTGGTTGGAGTC SEQ ID 35 Pr3-30 Homo sapiens geminin mRNA (mutation at nt 220) GCGGAGTTAGCAGGGCTTTACTGCAGAGCGCGCCGGGCACTCCAGCG ACCGTGGGGATCAGCGTAGGTGAGCTGTGGCCTTTTGCGAGGTGCTG CAGCCATAGCTACGTGCGTTCGCTACGAGGATTGAGCGTCTCCACCC ATCTTCTGTGCTTCACCATCTACATAATGAATCCCAGTATGAAGCAGA AACAAGAAGAAATCAAAGAGAATATAAAGACTAGTTCTGTCCCAAGA AGAACTCTGAAGATGATTCAGCCTTCTGCATCTGGATCTCTTGTTGGA AGAGAAAATGAGCTGTCCGCAGGCTTGTCCAAAAGGAAACATCGGAA TGACCACTTAACATCTACAACTTCCAGCCTGGGGGTTATTGTCCCAGA ATTCTAGTGAAAATAAAAATTTNGNNGGGAGTCACCCANGGAGTATTT TTGATCTTATGATTAAAGGAAAATCCATCTTTTAATATTGAAGGGGAA GNGGGCAGAAAAACGGAAAAGGGGNCCTTTNTGAAGCACTTAAGGGA AAATGAGNAAACTTCATAAAGNAAATTGACCAAANGGACAATTGAAA ATGGCCCGCTGAAAAAGGAAAATAAAGACTGGCNNNAAGTAGCAAAA CATGTCCNGGTTTTTG SEQ ID 36 Pr3-43 Homo sapiens DNA-binding protein (HRC1) mRNA ( 5'end of the clone corresponds to the beginning ofexon 2 ofHRCl) CAGGCATGTTGTTGGGACTGGCGGCCATGGAGCTGAAGGTGTGGGTG GATGGCATCCAGCGTGTGGTCTGTGGGGTCTCAGAGCAGACCACCTG CCAGGAAGTGGTCATCGCACTAGCCCAAGCAATAGGCCAGACTGGCC GCTTTGTGCTTGTGCAGCGGCTTCGGGAGAAGGAGCGGCAGTTGCTG CCACAAGAGTGTCCAGTGGGCGCCCAGGCCACCTGCGGACAGTTTGC CAGCGATGTCCAGTTTGTCCTGAGGCGCACAGGGCCCAGCCTAGCTG GGAGGCCCTCCTCAGACAGCTGTCCACCCCCGGAACGCTGCCTAATT CGTGCCAGCCTCCCTGTAAAGCCACGGGCTTGCGCTTGGGCTGTGAG CCCCGCAAAACACTGACCCCGAGCCAGCCC SEQ ID 37 Pr3-49 Homo sapiens vesicle docking protein pi 15 mRNA CCGAGTTGGAGGCGGTGGAGCCAGCAGTAGGAGTGTGTAGAGTGCG GGATTGGGGGCCAGGCCCTGCGGAGGGCGGGGGAAGTTGTCTTCTTT TTTTTCCGGAGGGGCCGGTAAACCTGGTGGCTGAACGGCAAGATGAA TTTCCTCCGCGGGGTAATGGGGGCTCAGAGTGCCGGACCCCAGCACA CAGAAGCCGAGACGATTCAAAAGCTTTGTGACAGAGTAGCTTCATCT ACTTTATTGGATGATCGAAGAAATGCTGTTCGTGCTCTCAAATCATTA TCTAAGAAATACCGCTTGGAAGTGGGTATACAAGCTATGGAACATCTT ATTCATGTTTTACAAACAGATCGTTCANATTCTGAAATTATAGGTATG CTTTGGACACACTATATAATNNATATCTAA SEQ ID 38 Pr3-101 Homo sapiens upstream transcription factor, c-fos interacting (USF2) ACATGCTGGACCCGGGTCTGGATCCCGCTGCCTCGGCCACCGCTGCT GCCGCCGCCAGCCACGACAAGGGACCCGAGGCGGAGGAGGGCGTCG AGCTGCAGGAAGGCGGGGACGGCCCAGGAGCGGAGGAGCAGACAGC GGTGGCCATCACCAGCGTCCAGCAGGCGGCGTTCGGCGACCACAACA TCCAGTACCAGTTCCGCACAGAGACAAATGGAGGACAGGTGACATAC CGCGTAGTCCAGGTGACTGATGGTCAGCTGGACGGCCAGGGCGACAC AGCTGGCGCCGTCAGCGTCGTGTCCACCGCTGCTTCGCGGGGGGGCA AGCAGGCTGTGACCAGGTG GGTGTGC SEQ ID 39 Pr3-109 Homo sapiens DNA-binding protein (HRC1) mRNA (Type I transcript) GTCGGGGTGGGGCGTTCCCATGCCGGCGGCCGCGGGGCCTGGCGTG CGGGCGCCTCCGCGCCGCCCGGGGAGGGGGCAGTGTCCTCCGAGCC AGGACAGGCATGTTGTTGGGACTGGCGGCCATGGAGCTGAAGGTGTG GGTGGATGGCATCCAGCTGTGTGGTCNTGTGGGGTCTCAGAGCAGAC ACCTGCCAGGAAGTGGTCATCGCACTAGCCCAAGCAATAGGCCAGAC TGGCCGCTTTGTGCTTGTGCAGCGGCTTCGGGAGAAGGAGCGGCAGT TGCTTGCCACAAGAGTGTCCAAGTGGGCGCCCAGGCCACCTGCGGAC AGTTTGCCAGCGATGTCCAGTTTGTCCTGAGGCGCACAGGGCCCAGC CTAGCTGGGAGGCCTTCTAGACAGCTGC SEQ ID 40 Pr3-1 11 Homo sapiens proteasome sub-unit HSPC mRNA GAGTCGCGGCGGAAGGAGCCCGGCCGCCGCCCGCCGGCATGAGCTA CGACCGCGCCATCACCGTCTTCTCGCCCGACGGCCACCTCTTCCAAG TGGAGTACGCGCAGGAGGCCGTCAAGAAGGGCTCGACCGCGGTTGG TGTTCGAGGAAGAGACATTGTTGTTCTTGGTGTGGAGAAGAAGTCAG TGGCCAAACTGCAGGATGAAAGAACAGTGCGGAAGATCTGTGCTTTG GATGACAACGTCTGCATGGCCTTTGCAGGCCTCACCGCCGATGCAAG GATAGTCATCAACAGGGCCCGGGTGGAGTGCCAGAGCCACCGGCTGA CTGTGGAGGACCCGGTCACTGTGGAGTACATACCCGCTACATCGCCA GTCTGAAGCAGCGTTATACGCAC SEQ ID 41 Pr3-112 Homo sapiens trans-Golgi p230 mRNA GCCGAGGCCAGCCAGTGGCACCCGGAAGAAAGAGACGCGGCGGCGG CGACGCCGACACCCTCAGGACGAGTGTCCGGACTTGCCCACAGCCTC AAGGAGGAGACGGCGAGGCCCGGCCCCCGCTGTCCCTGGTGTAAAG AAGTCGCCGTAGCCGTCGCGGCCGGGACTCCCCGGGCTCTCGCCCTT CAGGTTTCGTTGACACTCAGGACCGTACGTACGCTTGCGCCATGTTC AAGAAACTGAAGCAAAAGATCAAGCGAGGAGCAGCAGCAGCTCCAGC AGGCGCTTGGCTCCTGCTCAGGCGTCCTCCAATTCTTCAACACCAACA AGAATGAGGAGCAGGACATCTTCATTTCAGAGCAACTTGATGAAGGT ACACCCAATAGAGAGTCAGGTGACACACAGTCTTTTGA SEQ ID 43 Pr3-118 Homo sapiens poly (ADP-ribose) polymerase mRNA (The clone is 14 nt longer than the polymerase at 5' end; There is a point mutation at nt 159 of the clone) GCCGCTCAGGCGCCTGCGGCTGGGTGAGCGCACGCGAGGCGGCGAG GCGGCAGCGTGTTTCTAGGTCGTGGCGTCGGGCTTCCGGAGCTTTGC CGGCAGCTAGGGGAGGATGGCGGAGTCTTCGGATAAGCTCTATCGAG TCGAGTACGCCAAGAGCGGGCGCGCCTCTTGCAAGAAATGCAGCGAG AGCATCCCCAAGGACTCGCTCCGGATGGCCATCATGGTGCAGTCGCC CATGTTTGATGGAAAAGTCCCACACTGGTACCACTTCTCCTGCTTCTG GAAGGTGGGCCACTCCATCCGGCACCCTGACGTTGAGGTGGATGGGT TCTCTGAGCTTCGGTGGGATGATCAAGCAGAAAGTCAAGAAGACAGC GGAAGCTGGAGGAGTNCAGG SEQ ID 44 Pr3-119 Homo sapiens tankyrase, TRF-interacting ankyrin-related polymerase (TNKS) mRNA, and translated products (point mutation at nt 129 of the clone) TAAAGGAAAGTATGAAATCTGCAAGCTCCTTTTAAAACATGGAGCAG ATCCAACTAAAAAGAACAGAGATGGAAATACACCTTTGGATTTGGTAA AGGAAGGAGACACAGATATTCAGGACTTACTGAGAGGGGATGCTGCT TTGTTGGATGCTGCCAAGAAGGGCTGCCTGGCAAGAGTGCAGAAGCT CTGTACCCCAGAGAATATCAACTGCAGAGACACCCAGGGCAGAAATT CAACCCCTCTGCACCTGGCAGCAGGCTATAATAACCTGGAAGTAGCT GAATATCTTCTAGAGCATGGAGCTGATGTTAATGCCCAGGACAAGGG TGGTTTAATTCCTCTTCATAATGCGGCATCTTATGGGCATGTTGACA SEQ ID 45 Pr3-128 Homo sapiens proteasome sub-unit HSPC mRNA GAAGAAACAAAAGAAAGCATCATGATGAATAAAATGTCTTTGCTTGTA ATTTTTAAATTCATATCAATCATGGATGAGTCTCGATGTGTAGGCCTT TCCATTCCATTTATTCACACTGAGTGTCCTACAATAAACTTCCGTATTT TTA SEQ ID 46 Pr3-146 Human poly(ADP-ribose) polymerase mRNA (point mutation at nt 140 of the clone) GCGATGNCTATTACTGCACTGGGGACGTCACTGCCTGGACCAAGTGT ATGGTCAAGACACAGACACCCAACCGGAAGGAGTGGGTAACCCCAAA GGAATTCCGAGAAATCTCTTACCTCAAGAAATTGAAGGTTAAAAAACA GGACCGTATATTCCCCCCAGAAACCAGCGCCTCCGTGGCGGCCACGC CTCCGCCCTCCACAGCCTCGGCTCCTGCTGCTGTGAACTCCTCTGCTT CAGCAGATAAGCCATTATCCAACATGAAGATCCTGACTCTCGGGAAG CTGTCCCGGAACAAGGATGAAGTGAAGGCCATGATTGAGAAACTCGG GGGGAAGTTGACGGGGACGGCCAACAAGGCTTCCCTGTGCATAAGCA CCAAAAAGGAGGTGGAAAAGATGAATAAGAAGATG SEQ ID 47 Pr3-152 Homo sapiens ribosomal protein L10 AGAACANGGAGCATGTGATTGAGGCCCTGCGCAGGGCCAAGTTCAAG TTTCCTGGCCGCCAGAAGATCCACATCTCAAAAAGTGGGGCTTCAAC AAGTTCAATGCTGATGAATTTGAAGACATGGTGGCTGAAAAGCGGCT CATCCCAGATGGCTGTGGGGTCAAGTACATCCCCAGTCGTGGCCCTC TGGACAAGTGGCGGGCCCTGCACTCATGAGGGCTTCCAATGTGCTGC CCCCCTCTTAATACTCACCAATAAATTCTACTTCCTGTCCAAAAAAAA AAA SEQ ID 48 Pr3-154 Homo sapiens clone Xu-3 immunoglobulin heavy chain variable region mRNA GTCGTGGACCTCCTGCACAAGAACATGAAACACCTGTGGTTCTTCCTC CTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAGTTACA GCAGTGGGGCGCAGGACTCTTGAAGCCTTCGGAGACCCTGTCCCTCA CCTGCGCNTGTCTATGGTGGGTCCTTAAGTGGTTATGGCTGGAGCNT GGATCCGCCAGCCCCCAGGGAAGGGGCTTGGAGTGGATTGGGGAAG TCGACCATCGTGGCAGCGCCAATTACCAGTCGGCCCTCCAGAGTCGA GTCTCCGTATCATTGGACACGTCCAAGAACCAGGTCTCCCTGAGGCT GAACTCAGTGACCGCCGCGGACACGGCTGTTTATNCTGTGCGAGAGG CCTAATATAAAGCAATGGCTCTATTTGGGC SEQ ID 49 Pr3-155 Homo sapiens phospholipase C, gamma 1 mRNA GCCAGATCACGTGGAGCCGGGGCGCCGACAAGATCGAGGGGGCCAT TGACATTCGTGAAATTAAGGAGATCCGCCCAGGGAAGACCTCACGGG ACTTTGATCGCTATCAAGAGGACCCAGCTTTCCGGCCGGACCAGTCA CATTGCTTTGTCATTCTCTATGGAATGGAATTTCGCCTGAAAACGCTG AGCCTGCAAGCCACATCTGAGGATGAAGTGAACATGTGGATCAAGGG CTTAACTTGGCTGATGGAGGATACATTGCAGGCACCCACACCCCTGC AGATTGAGAGGTGGCTCCGGAAGCAGTTTTACTCAGTGGATCGGAAT CGTGAGGATCGTATATCAGCCAAGGACCTGAAGAACATGCTGTCCCA GGTCAACTACCGGGTCCCAACC SEQ ID 50 Pr3-157 Homo sapiens ribosomal protein S10 mRNA GTACCTTACCAATGAGGGTATCCAGTATCTCCGTGATTACCTTCATCT GCCCCCGGAGATTGTGCCTGCCACCCTACGCCGTAGCCGTCCAGAGA CTGGCAGGCCTCGGCCTAAAGGTCTGGAGGGTGAGCGACCTGCGAG ACTCACAAGAGGGGAAGCTGACAGAGATACCTACAGACGGAGTGCTG TGCCACCTGGTGCCGACAAGAAAGCCGAGGCTGGGGCTGGGTCAGC AACCGAATTCCAGTTTAGAGGCGGATTTGGTCGTGGACGTGGTCAGC CACCTCAGTAAAATTGGAGAGGATTCTTTTGCATTGAATAAACTTACA GCCAAAAAAACCTTA SEQ ID 51 Pr3-160 Homo sapiens poly(ADP-ribose) synthetase mRNA AATCCGGGCACCAGGTTCGGTGCCCTCCTTCCCTGCGAGGAATGCTC GGGTCAGCTGGTCTTCAAGAGCGATGCCTATTACTGCACTGGGGACG TCACTGCCTGGACCAAGTGTATGGTCAAGACACAGACACCCAACCGG AAGGAGTGGGTAACCCCAAAGGAATTCCTGAGAAATCTCTTACCTCA AGAAATTGAAGGTTAAAAAACAGGACCGTATATTCCCCCCAGAAACC AGCGCCTCCGTGGCGGCCACGCCTCCGCCCTCCACAGCCTCGGCTCC TGCTGCTGTGAACTCCTCTGCTTCAGCAGATAAGCCATTATCCAACAT GAAGATCCTGACTCTCGGGAAGCTGTCCCGGAACAAGGATGAAGTGA AGGCATGATTGAGAAACTCGGGGGGAAGTTGACGGGGA SEQ ID 52 Pr3-163 Homo sapiens mitochondrial DNA (A point mutation at nt 169 of the clone) AGGCTATGTGTTTTGTCAGGGGGTTGAGAATGAGTGTGAGGCGTATT ATACCATAGCCGCCTAGTTTCAAGAGTACTGCGGCAAGTACTATTGAC CCAGCGATGGGGGCTTCGACATGGGCTTTAGGGAGTCATAAGTGGAG TCCGTAAAGAGGTATCTTTACTATAAAGGCTATTGTGTAAGCTAGTCA TATTAAGTTGTTGGCTCAGGAGTTTGATAGTTCTTGGGCAGTGAGAGT GAGTAGTAGAATGTTTAGTGAGCCTAGGGTGTTGTGAGTGTAAATTA AGTGCGATGAGTAGGGGAAGGGAGCCTACTAGGGTGTAGAATAGGA AGTATGTCCTGCGTTCAGGCGTTCTGCTGGTTGCCTCATCGGGTGAT GATAGCCAAGGTGGGGATAAGTGTGGTTCCAAAC SEQ ID 53 Pr3-165 Homo sapiens ribosomal protein S8 GAGCGATGGGCATCTCTCGGGACAACTGGCACAAGCGCCGCAAAACC GGGGGCAAGAGAAAGCCCTACCACAAGAAGCGGAAGTATGAGTTGG GGCGCCCAGCTGCCAACACCAAGATTGGCCCCCGCCGCATCCACACA GTCCGTGTGCGGGGAGGTAACAAGAAATACCGTGCCCTGAGGTTGGA CGTGGGGAATTTCTCCTGGGGCTCAGAGTGTTGTACTCGTAAAACAA GGATCATCGATGTTGTCTACAATGCATCTAATAACGAGCTGGTTCGTA CCAAGACCCTGGTGAAGAATTGCATCGTGCTCATCGACAGCACACCG TACCGACAGTGGTACGAGTCCCACTATGCGCTGCCCTGGGCCGCAAG AAGGGAGCCAAGCTGACT SEQ ID 54 Pr3-168 Homo sapiens ubiquitin specific protease 8 (USP) mRNA GGCACATTGGCTAAAGGCTCTTTGGAGAATGTTTTGGATTCCAAAGA CAAAACCCAAAAGAGCAATGGTGAAAAGAATGAAAAATGTGAGACCA AAGAGAAAGGAGCAATCACAGCAAAGGAACTATACACAATGATGACG GATAAAAACATCAGCTTGATTATAATGGATGCTCGAAGAATGCAGGA TTATCAGGATTCCTGTATTTTACATTCTCTCAGTGTTCCTGAAGAAGC CATCAGTCCAGGAGTCACTGCTAGTTGGATTGAAGCACACCTGCCAG ATGATTCTAAAGACACATGGAAGAAGAGGGGGNAATGTGGAGTATTG TGGGTACTTCTTGACTGGGTTTAAGTTCTGCCAAAGATTTACCAGATT GGAACCAACTCTCCCGGAGTTTGAAAGATGCACTTTTCAGGGGGGAA AGTAAAACTGGTCCTGCNCATGAGCCTTTGGNTTTAANGGGGGGTTT GAAACTGGTCCTTTTTNTNCCCCGTTTCCACAAGCTTANGGGCNTCCC CCNCACCCNANAAAANNGGGNTTCATNGGGTTTNCTTTCCCTTNGGAA AAAAAATCTTTTAAACGGGGNCCACCCCCCCTTTTTAAAAN SEQ ID 55 Pr3-170 Homo sapiens sgk protein kinase TACCNTGTTTGNGCTCGCGCGCCTGCAGGTCGACACTAGTGGATCCA AAG CAACTCCATTGGCAAGTCCCCTGACAGCGTCCTCGTCACAGCCAGCG TCAAGGAAGCTGCCGAGGCTTTCCTAGGCTTTTCCTATGCGCCTCCCA CGGACTCTTTCCTCTGAACCCTGTTAGGGCTTGGTTTTAAAGGATTTT ATGTGTGTTTCCGAATGTTTTAGTTAGCCTTTTGGTGGAGCCGCCAGC TGACAGGACATCTTACAAGAGAATTTGCACATCTCTGGAAGCTTAGCA ATCTTATTGCACACTGTTCGCTGGAAGCTTTTTGAAGAGCACATTCTC CTCAGTGAGCTCATGAGGTTTTCATTTTTATTCTTCCTTCCAACGTGG TGCTATCTCTGAAACGAGCGTTAAGAGTGCCCGCCTTAGACGGAGCA NGGAGTTTTCGTTAGAAAAGCGGACGCTGTTCTAAAAAANGTCTCTG GCAGATCTGTCTGGGCTGGTGATGACNAATATTATGAAAATGTGNCC TTTNTGAANAAAATGGGGTTAGCTTCNAACTTTCTTTCGCAAGGGTTC AAGTTTTTATTTNCCTTGGGAATNCCTGGGGAACCCCCGGGGAAGGG GGGATGCCNGANCAAAGGNTTTTGTTTAGCCNNAAGGGGACCTTGCG GACTNCACGGGGAAATTTNTTTGTTT SEQ ID 56 Pr3- 174 Homo sapiens mitochondrial genome GTCACCAAGACCCTACTTCTAACCTCCCTGTTCTTATGAATTCGAACA GCATACCCCCGATTCCGCTACGACCAACTCATACACCTCCTATGAAAA AACTTCCTACCACTCACCCTAGCATTACTTATATGATATGTCTCCATA CCCATTACAATCTCCAGCATTCCCCCTCAAACCTAA SEQ ID 57 Pr3-176 Homo sapiens metastasis associated 1 (MTA1) mRNA GGGACATCTCCAGCACCCTCATCGCCCTGGCCGACAAGCACGCAACC CTGTCAGTCTGCTATAAGGCCGGACCGGGGGCGGACAACGGCGAGG AAGGGGAAATAGAAGAGGAAATGGAGAATCCGGAAATGGTGGACCT GCCCGAGAAACTAAAGCACCAGCTGCGGCATCGGGAGCTGTTCCTCT CCCGGCAGCTGGAGTCTCTGCCCGCCACGCACATCAGGGGCAAGTGC AGCGTCACCCTGCTCAACGAGACCGAGTCGCTCAAGTCCTACCTGGA GCGGGAGGATTTCTTCTTCTATTCTCTAGTCTACGACCCACAGCAGAA GACCCTGCTGGCAGATAAAGGAGAGATTCGAGTAGGAAACCGGTACC AGGCAGACATCACCGACTTGTTAAAAGAAGGCGAGGAGGATGGCCGA GACCAGTCCAGGTTTGGAGACCCAAGTGTNGGGAGGGGCACAACCCA CTTACAGACAAGCCAGATGNNCATTCTTGGGNGGNGGGCCGCTTTTG GGGCACCTTCCACGGGNCCTGGACTGAGANNTTTCTTCCACACCCAC TTGCAAAGANCNCCNAATTGCTTCCNAAAATANNCCTTTTCCNCCCCT GGGTTCTTTCAAAANAAATTTACAAATTTCAGGC SEQ ID 58 Pr3-179 Homo sapiens trans-Golgi p230 mRNA CCGAGGCCAGCCAGTGGCACCCGGAAGAAAGAGACGCGGCGGCGGC GACGCCGACACCCTCAGGACGAGTGTCCGGACTTGCCCACAGCCTCA AGGAGGAGACGGCGAGGCCCGGCCCCCGCTGTCCCTGGTGTAAAGA AGTCGCCGTAGCCGTCGCGGCCGGGACTCCCCGGGCTCTCGCCCTTC AGGTTTCGTTGACACTCAGGACCGTACGTACGCTGCGCCATGTTCAA GAAACTGAAGCAAAAGATCAGCGAGGAGCAGCAGCAGCTCCAGCAG GCGCTGGCTCCTGCTAGGCGTCCTCCAATTCTTCAACACCAACAAGA ATGAGGAGCAGGACATCTTCATTTACAGAGCAACTTGATGNAAGGTA CACCCAATAGAAGAGTTCAAGGTGGACACACAAGTCTTTTGCACAGA AAGCTTCAGTTCCNGGTGCCCTCGGGGGAGTCTTTGTTTTNGAAGTC CGATAAGGAATTNTTTTCCGGNCTTTTTTAAAGAGTTTTTTGGTCCAA AATNTTTCAAAAAATCCTGAATGATTGACTGGAAGNTCTGCCGTTTTG ATCCCCCTTTTTTGATGNNGGGTAAAAATTGGGGGGGATTTNANACG NTTAAAAAAAAATGTTTTCNGGTTGNAAAAAAGAANAANN SEQ ID 59 Pr3-186 Homo sapiens Surf-5 and Surf-6 genes AGAAAACACAAAAGAAATTCCGGAAGCGAGAAGAGAAGGCTGCTGAG CACAAGGCCAAGTCCTTGGGGGAGAAATCTCCAGCAGCCTCTGGGGC CAGGAGGCCTGAGGCAGCCAAAGAGGAAGCAGCTTGGGCTTCCAGCT CAGCAGGGAACCCTGCAGATGGCCTGGCCACTGAGCCTGAGTCTGTC TTTGCTCTGGATGTTCTGCGACAGCGACTGCATGAGAAGATCCAGGA GGCCCGGGGCCAGGGCAGTGCCAAGGAGCTGTCCCCTGCCGCCTTG GAGAAAAGGCGGCGGAGAAAGCAGGAACGGGACCGGAAGAAGAGGA AGCGAAAGGAGCTGCGGGCGAAAGANAAGCCAGGAAGGCTGAGGAG GCCACGGAGGCCCAGGAGGTGGTGGAGGCAACCCCAGAGGGGGCCT GCACGGACCNCANGAGCCCCCGGCTTGTCTTCATTAGGGGGGAGGTG AGCGAAACAACCGGCCACAAGGGGCACCAAAAAAAAAAAAGCANAGG TGAAGGGAACCTCNCCCTNCCGGAGAATACCGCANTTTTGAACCTGC GCNCCGAAAACCGTTGANAANTCGCCCNATGGGGGAAGCCCNGACTG GGCAAANA SEQ ID 60 Pr3-197 Homo sapiens calcium binding protein (ALG-2) mRNA (6 nt deletion and a point mutation) GGTCTCTCGTCGCTGCAGGCGCCTCAGCCCAGCCGCGTGCCTTGGCC CATGGCCGCCTACTCTTACCGCCCCGGCCCTGGGGCCGGCCCTGGGC CTGCTGCAGGCGCGGCGCTGCCGGACCAGAGCTTCCTGTGGAACGTT TTCCAGAGGGTCGATAAAGACAGGAGTGGAGTGATATCAGACACCGA GCTTCAGCAAGCTCTCTCCAACGGCACGTGGACTCCCTTTAATCCAGT GACTGTCAGGTCGATCATATCCATGTTTGACCGTGAGAACAAGGCCG GCGTGAACTTCAGCGAGTTCACGGGTGTGTGGAAGTACATCACGGAC TGGCAGAACGTCTTCCGCACGTACGACCGGGACAACTCCGGGATGAT CGATAAGAACGAGCTGAAGCAGGCCCTCTCAGGCTACCGGCTTNTNT GACCAGTTCCACGACATCCTATTCGAAAAGTTTGACAGGCAGGGACG GGGCAAAATCGCTTCAACACTTTATCANGGCTGNATTGTCTGAANAG GTGGCGGTNTTTTAAACTTCACCCGGATAGGANGTGTTTAAGGGGTC ACNAAAAANCTGCCANGNTTTAAAANTCGAAGACNGCCCCTTGGGAG GGCCCCACTNGGAAGGCCAATGTNCCNT SEQ ID 61 Pr3-200 Mus musculus BS4 peptide mRNA GCGCAGGGATGGCACAAAAGAAATATCTTCAAGCAAAATTGACCCAG TTTTTAAGGGAAGACAGGATTCAACTTTGGAAACCTCCATATACAGAT GAAAATAAAAAAGTTGGTTTGGCATTAAAGGACCTTGCTAAGCAGTA CTCTGACAGACTAGAATGCTGTGAAAATGAAGTAGAAAAGGTAATAG AAGAAATACGTTGCAAGGCAATTGAGCGTGGAACAGGAAATGACAAT TATAGAACAACGGGAATTGCTACAATCGAGGTGTTTTTACCACCAAGA CTAAAAAAAGATAGGAAAAACTTGTTGGAGACCCGATTGCACATCAC TGGCAGAGAACTGAGGTCCAAAATAGCTGAAACCTTTGGACTTCAAG AAAATTATATCAAAATTGTCATAAATAAGAAGCAACTACACTAGGGAA AACCCTTGAAGAAAAGGCGTGGCTCCAATGTGAAAGCGATGGTGCTT GACTAAAACATCTGAAAGGACGCAGGAAACTTCCGTTGGGGAAGAGA 'GCAAAANAGGCCACTCAAGAAAACANTCGNGNCAGANGGCTTGAATC TGGCAGAAGCACNAAAGNGGGGGACCAAAGAACCCNCTTTAACTTNT TACNGNCGGCNATN SEQ ID 62 Pr3-203 Homo sapiens Pigl 1 (PIG1 1 mRNA) GGCTCTGGCACACAGCTGTGCTCACAAAATACTGGGTGGCTTGGTTA GAGCTAATTGTAGTGGAGCCTGCAGGTGAGGGTGAGGGAGGGGGCT GCAGGTCAGGTAAGATCTGGAAGACAGACGTCAGCTTGGAGGGCAG GGGGACTCTAAGGCAAGGAGATTTACAGTTGGGAAGGAGGCAGTGG CAGAGGGGTGAGGGACAGGGGCCCTTAAGTCCAGCGAGGAAAGCTC GGTGTGGGCCCGCTCTACGCTCCGTTTGGGGTGACCTGGAACGCCTC TTCTCCCAGCTCCCTCCAGCCATCAGCAGCCTCTTGTCAAGCTTCTGC CTCGCCCCAGTCTATCCCCAACCCCAAATCAAGACCACCTTTCTTCAC GGTCACTATTTATTCTTTGGTCCTTTTCTTTTTGTAAGAAACATTCACA AAAACCAGTGCCNNNCCCNNNNNNNNNNNN^ ^M MNNNN NNNNNNAAAAACTCGGGAGTCTTTTAAGGGGGCGNGGC CNTNGNTTTCCCCGGGGGGGCCCGGNAAAGGNCCCCATNCCTTTNGG GGGGGGGTTNNATNTGGGCCCGGNTTAAAACNTNGATNGNACCNCTG GCT SEQ ID 63 Pr3-206 Homo sapiens FIFO-type ATP synthase sub-unit d mRNA GCAGCCAGGGTCGGTGAAGGATCCCAAAATGGCTGGGCGAAAACTTG CTCTAAAAACCATTGACTGGGTAGCTTTTGCAGAGATCATACCCCAGA ACCAAAAGGCCATTGCTAGTTCCCTGAAATCCTGGAATGAGACCCTC ACCTCCAGGTTGGCTGCTTTACCTGAGAATCCACCAGCTATCGACTG GGCTTACTACAAGGCCAATGTGGCCAAGGCTGGCTTGGTGGATGACT TTGAGAAGAAGTTTAATGCGCTGAAGGTTCCCGTGCCAGAGGATAAA TATACTGCCCAGGTGGATGCCGAAGAAAAAGAAGATGTGAAATCTTG TGCTGAGTGGGGTGTCTCTCTCAAAGGCCAGGATTGTAGAATATGAA GAAAGAGATGGAGAAGATGAAAGAACTTAATTNCTTTTGATCAGATG ACCATTGANGGACTTGAATGAAGCTTTTCCAGAAACCAAATTAGACAA GAAAAAGTNTCCTATTGGNCTCACCANCCATTGGGAATTATAAAATGA GTCNGGAGGAAGTTTGGCCTTGNTACCATTTGGCCTTAAATATTATTT TCCC WN>πWNNNNNNNNNNNNNNNNNNN^ CTT SEQ ID 64 Pr3-209 Homo sapiens ribosomal protein LI 8a GCTGTCAAGCAGTTCCACGACTCCAAGATCAAGTTCCCGCTGCCCCA CCGGGTCCTGCGCCGTCAGCACAAGCCACGCTTCACCACCAAGAGGC CCAACACCTTCTTCTAGGTGCAGGGCCCTCGTCCGGGTGTGCCCCAA ATAAACTCAGGAACGCCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAC SEQ ID 65 Pr3-219 Human FACL5 for fatty acid coenzyme A ligase 5 GTTGCTGCTTCTCAGATGCCAAGACTATGTATGAGGTTTTCCAAAGAG GACTCGCTGTGTCTGACAATGGGCCCTGCTTGGGATATAGAAAACCA AACCAGCCCTACAGATGGCTATCTTACAAACAGGTGTCTGATAGAGC AGAGTACCTGGGTTCCTGTCTCTTGCATAAAGGTTATAAATCATCACC AGACCAGTTTGTCGGCATCTTTGCTCAGAATAGGCCAGAGTGGATCA TCTCCGAATTGGCTTGTTACACCGTACTCTATGGTAGCTTGTACCTCT GTATGACACCTTGGGACCAGAAGCCATCGTACATATTGTCAACAAGG CTGATATCGCCGTGGTGATCTGTGACACACCCCAAAAGGCATTGGTG CTGATAGGGAATGTAAGAAGGCTCACCC SEQ ID 66 Pr3-224 Homo sapiens DNA-binding protein (HRCl) mRNA (The clone contains alternative exon la; it might be a new isoform of HRCl) CCGGATNGGGTCTCCAGGCTGGCGAGCGCCCAGGCCAGACTGGCCG CTTTGTGCTTGTGCAGCGGCTTCGGGAGAAGGAGCGGCAGTTGCTGC CACAAGAGTGTCCAGTGGGCGCCCAGGCCACCCTGCGGACAGTTTGC CAGCGATGTCCAGTTTGTCCTGAGGCGCACAGGGCCCAGCCTAGCTG GGAGGCCCTCCTCAGACAGCTGTCCACCCCCGGAACGCTGCCTAATT CGTGCCAGCCTCCCTGTAAAGCCACGGGCTGCGCTGGGCTGTGAGCC CCGCAAAACACTGACCCCCGAGCCAGCCCCCAGCCTCTCACGCCCTG GGCCTGCGGCCCCTGTGACACCCACACCAGGCTGCTGCACAGACCTG CGGGCCTGAACTCAGGGTGCAGAGGAC

Claims: CLAIMS 1. The use of an isolated nucleic acid molecule comprising a sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID3, SEQ.ID4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l 1, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.5.6, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 to detect or monitor cancer. 2. The use of a nucleic acid probe which is capable of hybridising under high stringency conditions to an isolated nucleic acid molecule comprising a sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID.3, SEQ.ID.4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l 1, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.l 8, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 to detect or monitor cancer. 3. A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising a sequence selected from SEQ.ID. l, SEQ.ID.2, SEQ.ID.3, SEQ.ID.4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 in a sample from a patient. 4. A method of detecting or monitoring cancer comprising the use of a nucleic acid molecule or probe according to claim 1 or claim 2 in combination with a reverse transcription polymerase chain reaction (RT-PCR). 5. A method of detecting or monitoring cancer comprising detecting or monitoring elevated levels of a protein or peptide comprising an amino acid sequence encoded by a nucleic acid sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID.3, SEQ.ID.4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66. 6. A method according to claim 5 comprising the use of an antibody selective for a protein or peptide as defined in claim 5 to detect the protein or peptide. 7. A method according to claim 7 comprising the use of an Enzyme-linked Immunosorbant Assay (ELISA). 18. Use or method according to any one of claims 1 to 7, wherein the cancer is prostate cancer is prostate cancer. 9. A kit for use with a method according to any one of claims 3-8 comprising a nucleic acid, protein or peptide, or an antibody as defined in any one of claims 3-8. 10. A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of nucleic acid molecule comprising a nucleic acid sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID3, SEQ.ID4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 or a pharmaceutically effective fragment thereof. 11. A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of a nucleic acid molecule hybridisable under high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID3, SEQ.ID4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 or a pharmaceutically effective fragment thereof. 12. A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of a protein or peptide comprising an amino acid sequence encoded by a nucleic acid sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID3, SEQ.ID4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 or a pharmaceutically effective fragment thereof. 13. A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of an antibody capable of specifically binding a protein or peptide comprising an amino acid sequence encoded by a nucleic acid sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID3, SEQ.ID4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66. 14. A method according to any one of claims 10 to 11, wherein the cancer is prostate cancer. 15. A vaccine comprising a nucleic acid molecule having a nucleic acid sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID3, SEQ.ID4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14,SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 or a pharmaceutically effective fragment thereof and a pharmaceutically acceptable carrier. 16. A vaccine comprising a protein or peptide comprising an amino acid sequence encoded by a nucleic acid sequence selected from SEQ.ID.l, SEQ.ID.2, SEQ.ID3, SEQ.ID4, SEQ.ID.5, SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14,SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.31, SEQ.ID.32, SEQ.ID.33, SEQ.ID.34, SEQ.ID.35, SEQ.ID.36, SEQ.ID.37, SEQ.ID.38, SEQ.ID.39, SEQ.ID.40, SEQ.ID.41, SEQ.ID.42, SEQ.ID.43, SEQ.ID.44, SEQ.ID.45, SEQ.ID.46, SEQ.ID.47, SEQ.ID.48, SEQ.ID.49, SEQ.ID.50, SEQ.ID.51, SEQ.ID.52, SEQ.ID.53, SEQ.ID.54, SEQ.ID.55, SEQ.ID.56, SEQ.ID.57, SEQ.ID.58, SEQ.ID.59, SEQ.ID.60, SEQ.ID.61, SEQ.ID.62, SEQ.ID.63, SEQ.ID.64, SEQ.ID.65 and SEQ.ID.66 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier. 17. An isolated mammalian nucleic acid molecule comprising a nucleic acid sequence selected from SEQ.ID.6, SEQ.ID.7, SEQ.ID.8, SEQ.ID.9, SEQ.ID.10, SEQ.ID.l l, SEQ.ID.12, SEQ.ID.13, SEQ.ID.14, SEQ.ID.15, SEQ.ID.16, SEQ.ID.17, SEQ.ID.18, SEQ.ID.19, SEQ.ID.20, SEQ.ID.21, SEQ.ID.22, SEQ.ID.23, SEQ.ID.24, SEQ.ID.25, SEQ.ID.26, SEQ.ID.27, SEQ.ID.28, SEQ.ID.29, SEQ.ID.30, SEQ.ID.43, SEQ.ID.44, SEQ.ID.52, SEQ.ID.60 and SEQ.ID.66 or a variant of a fragment thereof which encodes a prostate-associated antigen which is expressed in higher than normal concentrations in prostate cancer cells. 18. A vector comprising an isolated mammalian nucleic acid molecule according to claim 17. 19. A nucleic acid molecule comprising at least 15 nucleotides, the nucleic acid molecule being capable of hybridising to a molecule according to claim 17 under high stringency conditions. 20. An isolated protein or peptide comprising an amino acid sequence obtainable from a nucleic acid molecule according to claim 17, 18 or 19. 21. A nucleic acid probe capable of hybridising to a nucleic sequence as defined in SEQ ID 34, SEQ ID 35, SEQ ID 43, SEQ ID 44, SEQ ID 52, SEQ ID 60, SEQ ID 65 or SEQ ID 66, or a sequence complementary thereto, under high stringency conditions.

Inventors: LI GENG, MIAN SHAHID, REES ROBERT CHARLES, LI, GENG, MIAN, SHAHID, REES, ROBERT, CHARLES
Applicants: LI GENG, MIAN SHAHID, REES ROBERT CHARLES, UNIV NOTTINGHAM TRENT, LI, GENG, MIAN, SHAHID, REES, ROBERT, CHARLES, THE NOTTINGHAM TRENT UNIVERSITY
Application year: 2001
Main classification: C12Q1
IPC codes: A61K48, C12N9